Literature DB >> 6149294

Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice.

J R Haigh, J P Gent, R Calvert.   

Abstract

The anticonvulsant effects of acute administration of clobazam and its principal metabolite N-desmethylclobazam were studied in mice. Pentetrazol, given by slow intravenous infusion 1 or 2 h after the anticonvulsant dose, was used as the convulsant stimulus. Log dose response relationships for both clobazam and N-desmethylclobazam appeared linear, but there was no correlation between plasma concentrations of clobazam and protection. However, correlation between plasma concentrations of N-desmethylclobazam and protection was significant in both cases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149294     DOI: 10.1111/j.2042-7158.1984.tb04917.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

Review 1.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

2.  Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats.

Authors:  J Dingemanse; R A Voskuyl; M W Langemeijer; I Postel-Westra; D D Breimer; H Meinardi; M Danhof
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

3.  Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure.

Authors:  J Dingemanse; F A Sollie; D D Breimer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

4.  N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

Authors:  J R Haigh; T Pullar; J P Gent; C Dailley; M Feely
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

5.  Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.

Authors:  Orrin Devinsky; Elizabeth A Thiele; Stephen Wright; Daniel Checketts; Gilmour Morrison; Eduardo Dunayevich; Volker Knappertz
Journal:  Acta Neurol Scand       Date:  2020-07-17       Impact factor: 3.209

6.  A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
.

Authors:  Brooks Boyd; Steven Smith; Arnold Gammaitoni; Bradley S Galer; Gail M Farfel
Journal:  Int J Clin Pharmacol Ther       Date:  2019-01       Impact factor: 1.366

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.